Valeant finds second maker for Methoxsalen; Teva consolidating plants;

> Valeant Pharmaceuticals ($VRX) says the FDA has approved a second manufacturer for methoxsalen USP, used in the treatment of psoriasis, that previously had been in short supply. Release

> In its earnings call, Teva ($TEVA) said it was going through a "rationalization plan" worldwide and will close a number of its 120 plants over the next two to three years. It reported that at 32% decline in generic revenues in the U.S. came in part from quality and supply issues from plants in Irvine and Jerusalem. Release | Earnings transcript

> Sanofi's ($SNY) Genzyme unit has recalled one batch of the leukemia drug Fludara made at the closed Ben Venue Laboratories plant in Bedford, OH, due to concerns about its sterility--the latest in a series of supply and quality issues at the plant. Story

> Johnson & Johnson ($JNJ) continued to market an artificial hip in Europe and elsewhere overseas after the FDA rejected it in the U.S. based on a review of company safety studies. News

> Asymchem Laboratories has opened a $20M manufacturing facility called Jilin Asymchem Laboratories, in Dunhua, PR China. Story

> Lonza says a deal for a partnership with South Africa to build an API plant is still being negotiated. Item

> Hospitals are torn over federal rules for discarding expired but scarce drugs. Report

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.